Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Carolina Infusion
WARNING LETTER
•Carolina Infusion•August 12, 2022

Carolina Infusion – FDA Warning Letter, Aug 12, 2022

Record Details

The FDA issued a Warning Letter to Carolina Infusion following a July-August 2022 inspection, citing serious deficiencies in their production of non-sterile and sterile drug products. The firm failed to meet section 503A conditions by not receiving valid patient-specific prescriptions for some compounded products, thus losing exemptions from CGMP, labeling, and FDA approval requirements. Drug products intended to be sterile were adulterated under section 501(a)(2)(A) due to insanitary conditions. Violations included using unverified materials for endotoxin control, poor facility design allowing air influx, using non-pharmaceutical grade components, inadequate media fills, and ISO-5 areas not dynamically certified. The firm also produced unapproved new drugs (sections 505(a), 301(d)) and misbranded drugs (section 502(f)(1)) lacking adequate directions for use. While the firm recalled sterile products and ceased intrathecal production, many corrective actions were deemed inadequate or lacked documentation. These included issues with endotoxin testing, component verification, certification reports, and environmental monitoring. Unaddressed concerns involved endotoxin control and limits for intrathecal products, inadequate pressure differentials, and media fills not reflecting complex compounding. The FDA strongly recommended a comprehensive third-party assessment, especially if sterile intrathecal production resumes. Failure to address violations could lead to legal action.

Company
Carolina Infusion
Inspection date
August 12, 2022
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations II
Person
  • Monica R. Maxwell (Program Division Director)
View Company Profile

ID · 74f61c8a-7e90-4f9e-b9ff-04365b24d48a

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 353a21 U.S.C. 352(f)(1)21.U.S.C. 355(a)21 U.S.C. 331(k)FD&C Act 505FD&C Act 501(a)(2)(B)FD&C Act 502(f)(1)FD&C Act 301(a)FD&C Act 301(d)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Carolina Infusion
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.